Drug Search Results
More Filters [+]

Doravirine

Alternative Names: doravirine, mk-1439, pifeltro, mk1439, mk 1439, delstrigo
Latest Update: 2024-12-06
Latest Update Note: Clinical Trial Update

Product Description

Doravirine (brand name: Pifeltro) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults who meet certain requirements, as determined by a health care provider. Doravirine is always used in combination with other HIV medicines. (Sourced from: https://clinicalinfo.hiv.gov/en/drugs/doravirine/patient)

Mechanisms of Action: NNRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Mexico | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States

Approved Indications: HIV Infections | HIV Infections

Known Adverse Events: Abdominal Pain | Dizziness | Headache | Pain Unspecified | Diarrhea

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Doravirine

Countries in Clinic: Argentina, Australia, Brazil, Cambodia, Cameroon, Canada, Chile, Colombia, Finland, France, Germany, Israel, Italy, Japan, Korea, Malaysia, Mexico, Mozambique, Netherlands, New Zealand, Peru, Poland, Portugal, Puerto Rico, Russia, South Africa, South Korea, Spain, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 35

Highest Development Phases

Phase 3: Communicable Diseases|HIV Infections

Phase 2: Acquired Immunodeficiency Syndrome

Phase 1: Healthy Volunteers|Lipid Metabolism Disorders|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-8591A-053

P3

Unknown Status

HIV Infections

2029-08-06

MK-1439-066

P2

Recruiting

HIV Infections|Acquired Immunodeficiency Syndrome

2028-03-04

ANRS0392s ELDORADO

P3

Unknown Status

HIV Infections

2027-09-01

ELDORADO

P3

Not yet recruiting

Communicable Diseases|HIV Infections

2026-11-01

Recent News Events